Tiltan Pharma
Jerusalem · Founded 2006
About Tiltan Pharma
One of the major advances in cancer research over the past decade has been the realization that tumor growth is dependent on the tumor's ability to recruit blood vessels from the neighboring tissue. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer, critical for the development of all solid tumors. This property is the basis for anti-angiogenic therapy, a promising novel strategy for treatment of cancer.
Company Facts
- Founded: 2006
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.5M
- Last round: Series Unknown (Feb 2014)
- Website: http://tiltanpharma.com
- Phone: +97286473836
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tiltan-pharma-2926515 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.